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Jessica S Elman1, Matthew Li2, Fangjing Wang1, Jeffrey M Gimble3 and Biju Parekkadan1,4*Abstract
Background: Bone marrow-derived mesenchymal stromal cells (BMSCs) are a cell population of intense exploration
for therapeutic use in inflammatory diseases. Secreted factors released by BMSCs are responsible for the resolution
of inflammation in several pre-clinical models. New studies have uncovered that adipose tissue also serves as a
reservoir of multipotent, non-hematopoietic stem cells, termed adipose-derived stromal/stem cells (ASCs), with
many common characteristics to BMSCs. We hypothesized that ASC and BMSC secreted factors would lead to a
comparable benefit in the context of generalized inflammation.
Findings: Proteomic profiling of conditioned media revealed that BMSCs express significantly higher levels of
sVEGFR1 and sTNFR1, two soluble cytokine receptors with known therapeutic activity in sepsis. In a prophylactic
study of endotoxin-induced inflammation in mice, we observed that BMSC secreted factors provided a greater
survival benefit and tissue protection of endotoxemic mice compared to ASCs. Neutralization of sVEGFR1 and
sTNFR1 did not significantly affect the survival benefit experienced by mice treated with BMSC secreted factors.
Conclusions: Our findings suggest that BMSCs may be more effective as a cell therapeutic for use in endotoxic
shock and that ASCs may be positioned for continued exploration in immunomodulatory diseases. Soluble cytokine
receptors can distinguish stromal cells from different tissue origins, though they may not be the sole contributors
to the therapeutic benefit of BMSCs. Furthermore, other secreted factors not discussed in this study may also
differentiate these stromal cell populations from one another.
Keywords: Soluble receptors, Mesenchymal stem cells, Adipose stem cells, Endotoxic shock, Tissue necrosis factor
alpha (TNF-α), Vascular endothelial growth factor (VEGF)Introduction
Sepsis is a systemic inflammatory response, typically trig-
gered by bacterial infection, that afflicts 750,000 people
each year, more than 210,000 of whom die [1]. The inflam-
matory response, designed to resolve the infection, affects
end-organ perfusion and exacerbates tissue injury leading
to multi-organ failure. Sepsis is associated with a surge of
systemic signaling molecules including cytokines and* Correspondence: biju_parekkadan@hms.harvard.edu
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reproduction in any medium, provided the orgrowth factors that can become uncontrollable [2]. The
body synthesizes naturally occurring soluble cognate re-
ceptors for these signaling ligands to regulate these path-
ways in vivo. Soluble receptors are generated by several
mechanisms, including proteolytic cleavage of receptor
ectodomains, alternative splicing of mRNA, and tran-
scription of genes that encode for the soluble receptor
[3]. These synthesized receptors preferentially bind their
ligand targets and render them inactive or, conversely,
increase their half-life [4]. Their role in the natural
progression of sepsis and many other diseases is under
investigation [5].td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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already been extremely successful on the market. Enbrel®
is an engineered version of a soluble tumor necrosis
factor alpha-α receptor 1 (sTNFR1) with a longer half-life
and is widely prescribed in autoimmune diseases such as
rheumatoid arthritis, psoriasis, and Crohn’s Disease [6].
Unfortunately, this treatment has had little success in sep-
sis [7]. Soluble vascular endothelial growth factor receptor
1 (sVEGFR1) was found to have pre-clinical benefit in a
model of bowel perforation leading to bacteremia [8]. A
clinical study (NCT01063010) is underway to measure the
benefit of reversing the pro-inflammatory, permeability-
promoting and procoagulant effects of VEGF at the level
of the endothelium based on this finding [9]. Combinator-
ial approaches to sepsis care that target multiple pathways
may be a more effective strategy.
Cell therapy is an alternative drug formulation that uses
living cells to achieve a higher-order therapeutic response
than a single molecule alone. Bone marrow-derived
mesenchymal stem cells (BMSCs) are a connective tissue
stem cell population that has been shown to modulate the
immune system [10,11]. Transplantation of BMSCs has
led to a therapeutic effect in a cecal-ligation sepsis model
that was the result of BMSC secreted factors [12]. In a
prior study, we reported that human BMSCs secreted
760 pg/106 cells of sTNFR1 [13]. Neutralizing BMSC-
derived sTNFR1 partially eliminated the therapeutic bene-
fit to lipopolysaccharide (LPS)-stimulated rats as a model
of cytokine response due to gram-negative bacterial in-
fection. Increasing evidence suggests that BMSC secrete
molecules that inhibit the effector function of immune
cells [14,15], although a more comprehensive view of
this immunotherapeutic continues to be sought. Adipose
tissue-derived stromal/stem cells (ASCs) are a recently
discovered cell population with much in common to their
bone marrow-derived counterpart. ASCs are an attractive
alternative cell therapy to BMSCs because they can be
obtained by less invasive means and are found at a much
higher frequency in donor tissue. BMSCs only exist at ap-
proximately 0.01% of total nucleated bone marrow cells.
ASCs are 500 times more prevalent within an equivalent
volume of adipose tissue [16]. Both cell populations have
been shown to be effective in certain pre-clinical studies
and to mechanistically inhibit the activation of T cells [17].
ASCs and BMSCs have yet to be compared in a model of
sepsis and for other anti-inflammatory potency.
In this communication, we present a comparison study
of ASCs and BMSCs with a focus on the therapeutic
benefit of soluble cytokine receptors in mice suffering
from endotoxic shock. BMSCs secrete two soluble cytokine
receptors, sTNFR1 and sVEGFR1, in conditioned medium
(CM) analysis at dramatically higher levels than ASCs,
suggesting a more potent cell population. A prophylactic
study in mice subjected to LPS-induced sepsis confirmeda significant survival benefit of BMSC-derived secreted
factors compared to ASCs. A subsequent study in LPS-
treated mice showed no significant difference in the
survival benefit of BMSC-CM compared to conditions
in which neutralizing antibodies to sTNFR1 and sVEGFR1
were applied to BMSC-CM. This study indicates that
though there are differences in soluble cytokine recep-
tors in secretions of BMSCs compared to ASCs, other
factors may play a role in explaining the superior anti-




BALB/cJ mice (6 weeks) were purchased from The Jackson
Laboratory (Bar Harbor, ME) and were maintained in
accordance with Institutional and NIH guidelines. Experi-
ments were approved by the Institutional Animal Care
and Use Committee of the Center for Comparative
Medicine at the Massachusetts General Hospital.
MSC isolation and culture
Human bone marrow MSCs were isolated by differen-
tial adhesion from a 30 mL bone-marrow aspirate ob-
tained from the iliac crest of two human donors (Lonza,
Hopkinton, MA). Mononuclear cells (MNC) were isolated
from the bone marrow with ACK Lysis Buffer (Lonza),
then resuspended in MSC growth medium consisting of
Minimum Essential Medium Alpha supplemented with
10% FBS (Gibco, Grand Island, NY), 2% Penicillin-
Streptomycin (Sigma Aldrich, St. Louis, MO), 2.5 μg/L
FGF (R&D), 2 ml/L Gentamicin (Sigma Aldrich, St.
Louis, MO), and 2.2 g/L NaHCO3. MNCs were incu-
bated in 10-stack cell factories (Nunclon Delta Surface,
Rochester, NY) and allowed to adhere for one week in a
humidified tissue culture incubator at 37°C with 10%
carbon dioxide. On day 7 of growth, non-adherent cells
were removed with full replacement of the growth
media. Cells attached to the surface were expanded over
another two week period. A PBS rinse and media replace-
ment was performed on day 14. Cells were harvested at
day 21 using Trypsin-EDTA (CellGro, Manassas, VA).
BMSCs were frozen in cryovials at 1,000,000 cells per vial
in 1 mL of cryopreservation medium.
Adipose Stromal/Stem Cell (ASC) Preparation: Human
ASC were isolated from donated elective subcutaneous
lipoaspirates and abdominoplasty surgeries from two
donors under a protocol approved by the Pennington
Biomedical Institutional Review Board (PBRC #23040)
according to published methods [18,19]. Briefly, lipoas-
pirate tissues were washed with phosphate buffered sa-
line (PBS), digested for 1 hr in PBS supplemented with
1% bovine serum albumin, 0.1% collagenase type 1 and
2 mM CaCl2, and the stromal vascular fraction (SVF)
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temperature. The SVF cells were culture expanded in
DMEM/F12 Ham’s medium supplemented with 10% fetal
bovine serum and 1% antibiotic/antimycotic until >80%
confluent. The adherent ASCs were harvested by trypsin
digestion, characterized based surface immunophenotype
as determined by flow cytometry and by adipogenic and
osteogenic differentiation prior to cryopreservation in
aliquots of 106 cells suitable for future studies.
For expansion of master cell banks, cells were thawed,
resuspended in fresh expansion medium, and plated at a
density of 50 cells/cm2. After 5 days in culture, cells were
washed and given fresh media. Within 6–8 days later they
were harvested using 0.1% trypsin (Invitrogen, Grand
Island, NY) and replated. Cells were used for conditioned
media during passages 2–5.
Preparation of conditioned media (CM)
Cells between passages 2–5 at 80% confluency were
washed and MSC media was replaced with 15 ml of condi-
tioning media. Conditioning media consisted of Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with
2% Penicillin-Streptomycin, .05% BSA (Sigma Aldrich),
and 3.6 g/L NaHCO3. After 24 hours, media was collected
and cells were trypsinized and counted. CM was stored
at 4°C for up to two weeks. Concentrated CM was made
by centrifuging in Amicon Ultra-15 Centrifugal Filter
Units (Millipore, Billerica, MA) repeatedly at 4000 rpm.
Concentrated CM was used at a 25-fold concentration
of 2×106 cells/ml.
Survival study in endotoxemia-induced mice
Endotoxemia was induced with intraperitoneal (IP)
injections of 10 μg LPS in white female BALB/cJ mice,
followed by 1 ml BMSC-CM, ASC-CM, or saline (con-
trol) injections IP. There were 9 animals per group.
Mice were monitored for survival at several intervals
for 48 hours.
Measurement of sTNFR1, sVEGFR1, sVEGFR2, sTNFR2 in
CM
Concentrated CM was subjected to a human sTNFR1/
TNFRSF1A DuoSet ELISA Development System (R&D
Systems, Minneapolis, MN) according to manufacturer’s
protocol. Conditioning media served as the control. We
expanded CM analysis for other soluble receptor analytes
using a multiplexed Human Soluble Cytokine Receptor
Panel Kit (Millipore) per vendor instructions.
MSC-CM treatment following LPS stimulation in mice for
histological studies
Female BALB/cJ mice were given 10 μg LPS IP followed
by 1 ml BMSC-CM, ASC-CM, or saline (control) IP. There
were four animals per group. Kidney, lung, and liver wereharvested from each experimental group, as well as from
healthy mice, 24 hours later. Formalin-fixed, paraffin-
embedded samples were sectioned and subjected to
hematoxylin and eosin (H&E) staining. Magnifications
were at ×20. Blind analysis of neutrophil infiltration and
scoring of the histological samples were performed by a
certified veterinary pathologist. The following criteria were
graded: tubular degeneration in kidney, inflammation in
the lungs, and hepatocellular vacuolation and degener-
ation of the liver.
Antibody neutralization of soluble cytokine receptors in
BMSC-CM
To induce endotoxemia, female BALB/cJ mice were given
10 μg LPS IP. Mice were then given 1 mL BMSC-CM,
1 mL BMSC-CM and neutralizing sTNFR1 antibody,
1 mL BMSC-CM and neutralizing sVEGFR1 antibody, or
conditioning media not exposed to cells, which served as a
control. Dosage of neutralizing antibodies to sTNFR1 and
sVEGFR1 (R&D Systems) was calculated based on the
vendor’s instructions to apply 1000–6000 ng/ml antibody
in the presence of 300 ng/ml of soluble cytokine recep-
tor. Based on our previous measurements, there were
1.5 ng/ml of sTNFR1 in concentrated BMSC-CM. Thus,
we applied 25 ng/ml neutralizing sTNFR1 antibody to
BMSC-CM to bind and block most of the sTNFR1. There
were approximately 2 ng/ml of sVEGFR1 in BMSC-CM,
we applied 36 ng/ml of neutralizing sVEGFR1 antibody
to BMSC-CM. Mice were monitored for survival for
48 hours. This study was independently repeated with
the same treatment groups to arrive at the final cohort
numbers.
Statistical analysis
ELISA results were analyzed using an unpaired Student’s
t-test assuming a normal distribution. All data represents
the mean of the samples ± standard deviation. For survival
study analysis, a log rank test was performed. P < 0.05
values were considered statistically significant.
Results
Significantly increased secretion of sTNFR1 and sVEGFR1
in BMSC-CM versus ASC-CM
We began our study by measuring the presence of
sTNFR1 from human BMSCs in comparison to ASCs
derived from a lipoaspirate. Multiplex ELISA analysis of
concentrated CM (2×106 cells conditioned/ml of CM)
was used to detect soluble cytokine receptors specifically
related to the TNF-α and VEGF pathways. Stark differ-
ences in sTNFR1 and sVEGFR1 quantities were observed
between the two cell populations. BMSCs secrete over
six times as much sTNFR1 as ASCs (Figure 1a; BMSC:
731.6 ± 30 pg/106 cells, ASC: 116.5 ± 13 pg/106 cells,
P = 5.05 × 10-6). ASCs had nearly undetectable levels of
Figure 1 Differences in soluble receptor secretion by ex-vivo expanded stromal cell populations. BMSC-CM and ASC-CM was concentrated
25-fold, to a formulation that represented the collection of 2x106 cells per ml of CM. Control samples are basal media that was not conditioned by cells.
Shown are ELISA analysis of CM for soluble receptors, including (a) sTNFR1, (b) sVEGFR1, (c) sTNFR2 and (d) sVEGFR2. There was non-specificity of the
sVEGFR2 antibody pair when analyzing CM samples. BMSCs uniquely expressed high levels of sTNFR1 and sVEGFR1.
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1000.85 pg/106 cells of sVEGFR1 under the same condi-
tions (Figure 1b; P = 7.5×10-5). Other soluble cytokine
receptors (Figure 1c-d) did not differ significantly. These
data led to the hypothesis that BMSC secreted factors
would be more potent in a model of sepsis than ASC
factors.
BMSC-CM provides superior survival benefit compared to
ASC-CM in the prevention of endotoxic shock in mice
We exposed mice to a supraphysiological level of LPS as
a model of sepsis. In response to LPS stimulation, a sub-
ject’s immune system overwhelms the body with an ex-
aggerated cytokine response. We evaluated the potential
of CM derived from BMSCs to ASCs to prevent theFigure 2 BMSC-CM provides a greater survival benefit to LPS-treated
to induce endotoxemia, followed by either 1 ml of saline (control), 1 ml BM
significantly greater survival benefit in comparison to control (P = 0.924), wsequelae caused by this “cytokine storm” in vivo. Mice
received a single intraperitoneal injection of LPS (10 μg
per 25 g mouse), followed by 1 ml intraperitoneal injec-
tion of concentrated BMSC-CM or ASC-CM (25-fold;
2×106 cells conditioned/ml). This concentration was
used based on previous findings reported that this con-
centration regimen can induce a therapeutic response
in rodents [14,20]. As Figure 2 shows, mice that re-
ceived either saline or ASC-CM displayed significantly
higher levels of mortality than the BMSC-CM treated
group. By the end of the study, 78% of the BMSC-CM
animals were alive and recovering, whereas only 25% of
the ASC-CM and 11% of the control animals survived
(P = 0.007 of BMSC-CM vs. saline; P = 0.017 of BMSC-
CM vs ASC-CM; P = 0.924 of ASC-CM vs. saline).mice than ASC-CM. 10 ug LPS were administered IP to each mouse
SC-CM, or 1 ml ASC-CM IP. ASC-CM treated mice did not experience a
hereas BMSC-CM treated mice did (P = 0.007).
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induced injury compared to ASC-CM
The infiltration of neutrophils and macrophages into
different organs is a characteristic marker of the general
inflammation caused by endotoxic shock [21]. To visualize
the degree of protection to endotoxic organs, we harvested
the kidney, lungs, and livers from mice exposed to LPS and
treated with BMSC-CM and ASC-CM. Histological analysis
was performed one day after treatment to ensure a high
level of survival in all groups. Kidneys treated with BMSC-
CM exhibited the least neutrophilic infiltration and the
greatest preservation in tubule architecture (Figure 3a).
The BMSC-CM lungs (Figure 3b) also had unperturbed
alveoli, unlike the control or ASC-CM groups. Liver hist-
ology (Figure 3c) also revealed increased vacuolation and
degeneration in control and ASC-CM groups, in contrast
to the BMSC-CM-treated group. A blinded pathological
score for these tissues quantified the observations that
BMSC-CM treated mice collectively had the least amount
of end-organ damage (Figure 3d) and were significantly
different than ASC-CM treated mice (P < 0.05).
Neutralization of sTNFR1 and sVEGFR1 does not
statistically inhibit preventative effects of BMSC-CM on
endotoxic shock in mice
Neutralization of sTNFR1 and sVEGFR1 in BMSC-CM
was tested to determine if survival was caused by these
soluble cytokine receptors in vivo. In order to minimize
changes in the overall composition of CM, we used neu-
tralizing antibodies rather than engineering of cells with
genetic constructs that could potentially induce new
and possibly unknown factors. Mice received an intra-
peritoneal injection of LPS (10 μg per 25 g mouse)
followed by a 1 ml intraperitoneal injection of concen-
trated BMSC-CM (25-fold; 2×106 cells conditioned/ml),
BMSC-CM treated with neutralizing sTNFR1 antibody
(0.025 ug/ml), or BMSC-CM treated with neutralizing
sVEGFR1 antibody (0.036 ng/ml). We found that the
survival benefit from BMSC-CM was generally unaffected
by the neutralization of sTNFR1 and sVEGFR1. As Figure 4
shows, survival benefit insignificantly differs between
the groups that received the neutralizing antibodies
and the regular BMSC-CM. By the end of the 48-hour
study, 66% of the BMSC-CM, 44% of the neutralizing
sTNFR1 antibody-treated BMSC-CM, and 33% of the
neutralizing sVEGFR1 antibody-treated BMSC-CM mice
were alive and recovering. Of the LPS-treated control
mice, only 14% survived. This group differed signifi-
cantly from the neutralizing sTNFR1 antibody BMSC-
CM group (P < 0.05) and from the BMSC-CM group
(P < 0.05). These data suggest that factors other than
soluble cytokine receptors may contribute to the sur-
vival benefit BMSC-CM gives to mice suffering from
endotoxic shock.Discussion
ASCs and BMSCs display similar morphology and growth
characteristics when expanded ex vivo. Immunophenoty-
pically, they are both known to be positive for the classical
mesenchymal stromal cell markers CD105, CD44 CD90,
CD166, and negative for CD14, CD19, and CD45 [16].
There is a continued effort to understand the differences
between these MSCs, particularly as they are both being
advanced for cell immunotherapeutic purposes. ASCs
and BMSCs have comparable suppressive effects on the
growth of PHA-stimulated T cells, suggesting that they
have equal influence on the adaptive immune response
[9]. We explored their comparability in preventing innate
immune responses observed in endotoxic inflammation
and demonstrate a significant improvement of disease
indices by BMSC secreted factors. We discovered that
BMSCs secrete significantly greater amounts of two
soluble cytokine receptors, sTNFR1 and sVEGFR1, com-
pared to ASCs. Although these soluble cytokine receptors
can be considered potency markers unique to BMSCs,
other factors are likely to also be responsible for BMSCs’
therapeutic effects in systemic inflammatory responses.
sTNFR1 has been shown to block the effects of TNF-α,
an inflammatory cytokine that is released in response to
inflammation. With increased distress, TNF-α reaches
dangerously high levels and can eventually lead to death
[22]. TNF-α converting enzyme (TACE) has been impli-
cated as the enzyme that sheds sTNFR1 from TNFR1.
Upon sTNFR1’s release, it binds to circulating TNF-α and
prevents its inflammatory effects [11]. A study by Yagi
et al. demonstrated the value of circulating sTNFR1 re-
leased by intramuscular BMSC transplants in the attenu-
ation of septic shock in rodents. When BMSC transplants
were co-administered with a neutralizing sTNFR1 anti-
body, the cell therapy failed to prevent the infiltration of
inflammatory cells in the lungs, liver, and kidney [6]. The
downstream mechanism by which sTNFR1 is protective
remains to be determined. There is evidence that sTNFR1
may not just simply block TNF-α, but exert its effects by
inducing apoptosis in monocytes via transmembrane
TNF-α [12]. Waetzig et al. found that sTNFR1 boosts
TGFβ1, which in turn has the ability to inhibit T lympho-
cyte proliferation [13]. There is, however, a delicate bal-
ance of the sTNFR1/TNF-α axis where it has been
observed that low sTNFR1 levels stabilize TNF-α [23].
Further studies will be needed to unravel the mechanism
that BMSCs employ to make sTNFR1 and how this
soluble receptor modulates the immune system.
VEGF, an angiogenic factor that supports microcapil-
lary growth from existing vasculature, typically benefits
endothelial tissues [14]. Recent studies have shown that
elevated levels of VEGF in response to inflammation can
cause more hindrance than initially thought. A study by
Tsao et al. demonstrated that injecting mice with VEGF
Figure 3 Cell-specific attenuation of end-organ damage in LPS mice by BMSC-CM. One day following LPS and CM administration, tissue
was harvested for hematoxylin and eosin (H&E) staining. Sections were analyzed for detection of tubular degeneration in kidney, inflammation in
the lungs, hepatocellular vacuolation and degeneration of the liver. Magnifications are x20. (a) The renal cells of the healthy kidney appear to be
unperturbed in contrast with the pale and poorly defined cells of the LPS-treated mouse. The ASC-CM kidney presents with similarly pale renal
cells, whereas the BMSC-CM kidney resembles the healthy control. (b) Alveoli are generously and evenly distributed in the healthy lung compared
to the LPS-treated group, which appears more constricted. The BMSC-CM treated lungs also present with expansive and unaffected alveoli, but
the ASC-CM treated lungs are clearly devastated: alveoli are significantly smaller and sparser. (c) The healthy liver shows few signs of inflammation. The
LPS-treated liver has swollen hepatocytes with affected nuclei. Many unhealthy cells appear in the ASC-CM treated liver as well. The BMSC-CM treated
liver appears to have fewer necrotic hepatocytes. (d) Histological slides were blindly scored by a pathologist. (P < 0.05).
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mortality [8]. VEGF induces the expression of cell adhe-
sion molecules, which cause leukocytes to bind effectively
to the endothelium. This can lead to even greater localcytokine production. VEGF can be silenced by sVEGFR1,
the truncated form of membrane-bound VEGF receptor 1
[15]. Heightened sVEGFR1 levels can mitigate this devas-
tating cascade at the blood vessel scale. Mice treated with
Figure 4 LPS-treated mice experience insignificant benefit when treated with BMSC-CM compared to BMSC-CM with neutralizing
antibodies targeting sTNFR1 and sVEGFR1. 10 ug LPS were administered IP to each mouse to induce endotoxemia, followed by either 1 ml of
saline (control), 1 ml BMSC-CM, 1 ml BMSC-CM with neutralizing sTNFR1 antibody, or 1 ml BMSC-CM with neutralizing sVEGFR1 antibody IP.
BMSC-CM treated mice experienced a significantly greater survival benefit in comparison to control mice (P = 0.0454). Mice given BMSC-CM with
neutralizing sTNFR1 antibody also experienced a significantly greater survival benefit compared to control (P = 0.0225). The BMSC-CM with
neutralizing sVEGFR1 antibody group did not differ significantly from the control (P = 0.106) or from the neutralizing sTNFR1 antibody group
(P = 0.528). Finally, neither group that received a neutralizing soluble receptor antibody had a significantly different survival benefit compared to
the BMSC-CM treated group (neutralizing sTNFR1 antibody vs BMSC-CM P = 0.563; neutralizing sVEGFR1 antibody vs BMSC-CM P = 0.237).
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have demonstrated a survival rate of 100% [16]. Several
theories have been proposed to explain the dichotomous
nature of an anti-angiogenic factor, sVEGFR1, as a benefi-
cial influence in inflammatory disease. Some suggest that
high levels of sVEGFR1 in sepsis may promote hypocoa-
gulability by recruiting endogenous anti-coagulating mole-
cules, which counteract the tissue damage by allowing
microcirculation to remain open and permit the body to
recover more quickly from endotoxemia [15]. sVEGFR1
has also been shown to selectively activate endothelial
nitric oxide synthase (eNOS), which contributes to
arteriogenesis, angiogenesis, and mural cell recruit-
ment [17]. Apart from sepsis, the presence of sVEGFR1
is also thought to regulate angiogenesis by VEGF in the
setting of cancerous tumor growth [24]. The release of
sVEGR1 by BMSCs may have implications in the thera-
peutic use of this cell population as well as the en-
dogenous regulation of VEGF signaling in stromalized
microenvironments.
Our findings indicate, however, that modulating sVEGFR1
activity alone with a neutralizing antibody does not signifi-
cantly affect BMSC-CM’s benefit to sepsis survival. For
the studies utilizing neutralizing antibodies, the addition
of IgG to the BMSC-CM would ideally be used to control
for the presence of antibody in the neutralizing antibody-
treated CM. Its absence, however, is likely to be inconse-
quential because the bovine serum albumin IgG in the
CM acts as a sufficient control for the neutralizing anti-
body’s influence on the LPS-challenged mice.In conclusion, we have uncovered a potency advantage
of BMSCs compared to ASCs in a model of sepsis and a
unique expression pattern of soluble receptors that are
implicated in the resolution of inflammation. This study
can guide the positioning and monitoring of these cell
populations for therapeutic use in immune-mediated
disease and may have ramifications to endogenous stromal
cell biology.
Competing interests
Dr. Gimble is the co-founder, co-owner and Chief Scientific Officer at LaCell
LLC, a for-profit biotechnology company focusing on stromal/stem cell
related products isolated from discarded medical waste tissues, including
adipose and bone marrow.
Authors’ contributions
JE: conceived and performed experiments, analyzed data, and wrote the
manuscript. ML: conceived and performed survival study experiments. FW:
helped perform in vivo experiments. JG: contributed ASCs. BP: conceived and
performed experiments, and helped write the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported of the National Institutes of Health (R01EB012521
and K01DK087770) and the Broad Medical Research Program of The Broad
Foundation (BMRP498382) and Shriners Hospitals for Children.
Author details
1Center for Engineering in Medicine and Surgical Services, Massachusetts
General Hospital, Harvard Medical School and Shriners Hospital for Children
in Boston, Boston, MA 02114, USA. 2Harvard-MIT Health Sciences and
Technology, Cambridge, MA 02139, USA. 3Stem Cell Biology Laboratory,
Pennington Biomedical Research Center, Louisiana State University, Baton
Rouge, LA 70808, USA. 4Harvard Stem Cell Institute, Boston, MA 02115, USA.
Received: 20 November 2012 Accepted: 6 December 2013
Published: 7 January 2014
Elman et al. Journal of Inflammation 2014, 11:1 Page 8 of 8
http://www.journal-inflammation.com/content/11/1/1References
1. Le Gall J, Lemeshow S, Leleu G, Klar J, Huillard J, Rue M, Teres D, Artigas A:
Customized probability models for early severe sepsis in adult intensive
care patients. Intensive Care Unit Scoring Group. JAMA 1995, 273:644–650.
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl
J Med 2003, 348:138–150.
3. Fernandez-Botran R: Soluble cytokine receptors: their role in
immunoregulation. Faseb J 1991, 5:2567–2574.
4. Levine SJ: Mechanisms of soluble cytokine receptor generation.
J Immunol 2004, 173:5343–5348.
5. Weckmann AL, Alcocer-Varela J: Cytokine inhibitors in autoimmune
disease. Semin Arthritis Rheum 1996, 26:539–557.
6. Silva LC, Ortigosa LC, Benard G: Anti-TNF-alpha agents in the treatment of
immune-mediated inflammatory diseases: mechanisms of action and
pitfalls. Immunotherapy 2010, 2:817–833.
7. Warren HS: Strategies for the treatment of sepsis. N Engl J Med 1997,
336:952–953.
8. Tsao PN, Chan FT, Wei SC, Hsieh WS, Chou HC, Su YN, Chen CY, Hsu WM,
Hsieh FJ, Hsu SM: Soluble vascular endothelial growth factor receptor-1
protects mice in sepsis. Crit Care Med 2007, 35:1955–1960.
9. Shapiro NI, Aird WC: Sepsis and the broken endothelium. Crit Care 2011, 15:135.
10. Parekkadan B, Milwid JM: Mesenchymal stem cells as therapeutics. Annu
Rev Biomed Eng 2010, 12:87–117.
11. Bonfield TL, Nolan Koloze MT, Lennon DP, Caplan AI: Defining human
mesenchymal stem cell efficacy in vivo. J Inflamm (Lond) 2010, 7:51.
12. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K, Robey
PG, Leelahavanichkul K, Koller BH, Brown JM, et al: Bone marrow stromal
cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming
of host macrophages to increase their interleukin-10 production. Nat
Med 2009, 15:42–49.
13. Yagi H, Soto-Gutierrez A, Navarro-Alvarez N, Nahmias Y, Goldwasser Y, Kitagawa
Y, Tilles AW, Tompkins RG, Parekkadan B, Yarmush ML: Reactive bone marrow
stromal cells attenuate systemic inflammation via sTNFR1. Mol Ther 2010,
18:1857–1864.
14. Parekkadan B, van Poll D, Suganuma K, Carter EA, Berthiaume F, Tilles AW,
Yarmush ML: Mesenchymal stem cell-derived molecules reverse fulminant
hepatic failure. PLoS ONE 2007, 2:e941.
15. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood 2005, 105:1815–1822.
16. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J: Same or not the
same? Comparison of adipose tissue-derived versus bone marrow-derived
mesenchymal stem and stromal cells. Stem Cells Dev 2012, 21:2724–2752.
17. Zhu X, Shi W, Tai W, Liu F: The comparition of biological characteristics
and multilineage differentiation of bone marrow and adipose derived
Mesenchymal stem cells. Cell Tissue Res 2012, 350(2):277–287.
18. Yu GWX, Dietrich MA, Polk P, Scott LK, Ptitsyn AA, Gimble JM: Yield and
characterization of subcutaneous human adipose-derived stem cells by flow
cytometric and adipogenic mRNA analyzes. Cytotherapy 2010, 12:538–546.
19. Yu G, Floyd ZE, Wu X, Halvorsen YD, Gimble JM: Isolation of human adipose-
derived stem cells from lipoaspirates. Methods Mol Biol 2011, 702:17–27.
20. van Poll D, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW,
Yarmush ML: Mesenchymal stem cell-derived molecules directly modulate
hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008,
47:1634–1643.
21. Lowell CA, Berton G: Resistance to endotoxic shock and reduced neutrophil
migration in mice deficient for the Src-family kinases Hck and Fgr. Proc Natl
Acad Sci U S A 1998, 95:7580–7584.
22. Robertson CM, Coopersmith CM: The systemic inflammatory response
syndrome. Microbes Infect 2006, 8:1382–1389.
23. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilization of
the bioactivity of tumor necrosis factor by its soluble receptors. J Exp
Med 1992, 175:323–329.
24. Bautch VL: Endothelial cells form a phalanx to block tumor metastasis.
Cell 2009, 136:810–812.
doi:10.1186/1476-9255-11-1
Cite this article as: Elman et al.: A comparison of adipose and bone
marrow-derived mesenchymal stromal cell secreted factors in the
treatment of systemic inflammation. Journal of Inflammation 2014 11:1.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
